CN105188683A - 控释药物剂型 - Google Patents

控释药物剂型 Download PDF

Info

Publication number
CN105188683A
CN105188683A CN201480026334.4A CN201480026334A CN105188683A CN 105188683 A CN105188683 A CN 105188683A CN 201480026334 A CN201480026334 A CN 201480026334A CN 105188683 A CN105188683 A CN 105188683A
Authority
CN
China
Prior art keywords
doxycycline
dosage form
controlled release
weight
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480026334.4A
Other languages
English (en)
Chinese (zh)
Inventor
萨杰夫·钱德拉
希里什库马尔·库尔卡尼
普拉文·梅格拉吉·布塔达
阿施施·阿肖克劳·德斯穆克
道格拉斯·巴坎
米切尔·沃泽曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicis Pharmaceutical Corp
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Priority to CN202010448106.3A priority Critical patent/CN112007007A/zh
Publication of CN105188683A publication Critical patent/CN105188683A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480026334.4A 2013-03-15 2014-03-04 控释药物剂型 Pending CN105188683A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010448106.3A CN112007007A (zh) 2013-03-15 2014-03-04 控释药物剂型

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN304KO2013 2013-03-15
IN304/KOL/2013 2013-03-15
US13/890,173 US10842802B2 (en) 2013-03-15 2013-05-08 Controlled release pharmaceutical dosage forms
US13/890,173 2013-05-08
PCT/US2014/020251 WO2014149674A1 (en) 2013-03-15 2014-03-04 Controlled release pharmaceutical dosage forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010448106.3A Division CN112007007A (zh) 2013-03-15 2014-03-04 控释药物剂型

Publications (1)

Publication Number Publication Date
CN105188683A true CN105188683A (zh) 2015-12-23

Family

ID=54198667

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480026334.4A Pending CN105188683A (zh) 2013-03-15 2014-03-04 控释药物剂型
CN202010448106.3A Pending CN112007007A (zh) 2013-03-15 2014-03-04 控释药物剂型

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010448106.3A Pending CN112007007A (zh) 2013-03-15 2014-03-04 控释药物剂型

Country Status (8)

Country Link
US (1) US10842802B2 (enExample)
EP (1) EP2968179B1 (enExample)
JP (1) JP6417532B2 (enExample)
KR (1) KR102298473B1 (enExample)
CN (2) CN105188683A (enExample)
AU (1) AU2014237934B2 (enExample)
CA (1) CA2906378C (enExample)
WO (1) WO2014149674A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528983B2 (en) * 2014-05-12 2016-12-27 Anna Merritt Holmes Physicochemical modification and application of alginate gels for the controlled release of reagents in classical solution assays and microfluidic assays
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
CA2968316A1 (en) 2014-11-19 2016-05-26 Nestle Skin Health Sa Modified release doxycycline composition
ITUB20150279A1 (it) * 2015-03-09 2016-09-09 S I I T S R L Servizio Int Imballaggi Termosaldanti Sistema flottante per la cura dei sintomi delle affezioni gastriche
CN114340670A (zh) * 2019-07-11 2022-04-12 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1455665A (zh) * 2000-09-19 2003-11-12 第一制药株式会社 药物组合物
WO2007038867A1 (en) * 2005-10-04 2007-04-12 Mistral Pharma Inc. Controlled-release oral dosage form
WO2010038234A1 (en) * 2008-10-02 2010-04-08 Taro Pharmaceutical Industries Ltd. Combination product of spironolactone and doxycycline
US20100330131A1 (en) * 2005-06-24 2010-12-30 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20110319368A1 (en) * 2003-04-07 2011-12-29 Supernus Pharmaceuticals, Inc. Once daily formulations of tetracyclines
US20120100214A1 (en) * 2010-10-21 2012-04-26 Galderma S.A. Sustained-Release Tablet and Process for Preparing the Same

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5000886A (en) 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
ES2150017T3 (es) 1994-12-16 2000-11-16 Warner Lambert Co Proceso de encapsulacion de comprimidos en una capsula y formas de dosificacion solidas obtenidas por este proceso.
US6245350B1 (en) 1994-12-16 2001-06-12 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
JPH0995440A (ja) 1995-09-29 1997-04-08 Roussel Morishita Kk 徐放性製剤およびその製造方法
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
CN1126537C (zh) 1996-05-23 2003-11-05 株式会社三养社 可局部给药,可生物降解和持续释放的用于治疗牙周炎的药物组合物及其制备方法
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5780055A (en) 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
BR9810027A (pt) 1997-06-11 2000-09-12 Procter & Gamble Comprimido revestido por pelìcula para melhorada segurança do trato gastrintestinal superior
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
AU747549B2 (en) 1998-03-23 2002-05-16 General Mills Inc. Encapsulation of components into edible products
DE69940821D1 (de) 1998-10-09 2009-06-10 Gen Mills Inc Verkapselung empfindlicher flüssiger komponenten in eine matrix zur gewinnung diskreter lagerbeständiger partikel
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
RU2270695C2 (ru) 1999-03-17 2006-02-27 Дайити Фармасьютикал Ко., Лтд. Фармацевтическая композиция
US20030077301A1 (en) 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
CZ20022047A3 (cs) 1999-12-23 2003-09-17 Pfizer Products Inc. Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
FR2811571B1 (fr) 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
IN192750B (enExample) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
AU2002256092C1 (en) 2001-04-05 2009-10-15 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030104052A1 (en) 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2470016A1 (en) 2001-12-20 2003-10-23 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
WO2003075852A2 (en) 2002-03-07 2003-09-18 Advancis Pharmaceuticals Corporation Antibiotic composition
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
AUPS167602A0 (en) 2002-04-12 2002-05-16 F.H. Faulding & Co. Limited An improved modified release preparation
AU2003230935B2 (en) 2002-04-16 2008-08-07 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US8192749B2 (en) 2003-04-16 2012-06-05 Galderma Laboratories Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US20050266077A1 (en) 2002-06-20 2005-12-01 Royal Biomedical, Inc. Resorbable matrices with coatings for delivery of bioactive compounds
CA2490351C (en) 2002-06-25 2011-11-01 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
EP1417958A1 (en) 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
ES2645930T3 (es) 2003-01-03 2017-12-11 Supernus Pharmaceuticals, Inc. Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
MXPA05010636A (es) 2003-04-04 2005-12-12 Pharmacia Corp Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
US20040202693A1 (en) 2003-04-14 2004-10-14 Rong-Kun Chang Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
WO2004112713A2 (en) 2003-06-20 2004-12-29 Royer Biomedical, Inc. Drug polymer complexes
AU2004261143B2 (en) 2003-07-25 2009-11-05 Allergan Pharmaceuticals International Limited A doxycycline metal complex in a solid dosage form
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US20050049210A1 (en) 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
WO2005044242A1 (en) 2003-10-27 2005-05-19 Dow Corning Corporation Preparations for topical application and methods of delivering an active agent to a substrate
WO2005046651A1 (en) 2003-11-12 2005-05-26 Ranbaxy Laboratories Limited Liquid filled capsules of doxycycline
ATE399536T1 (de) 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
DE10358748A1 (de) 2003-12-12 2005-07-14 Lts Lohmann Therapie-Systeme Ag Darreichungsform basierend auf vernetzten hydrophilen Polymeren
US7410480B2 (en) 2004-04-21 2008-08-12 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
JP5154924B2 (ja) 2004-05-11 2013-02-27 エガレット エイ／エス ジェランガムを含む膨張可能な投与形態
CA2578709C (en) 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
US20080161273A1 (en) 2004-10-20 2008-07-03 Galderma Research & Development Method of Using Adapalene in Acne Maintenance Therapy
WO2006045152A1 (en) 2004-10-29 2006-05-04 Mayne Pharma International Pty Ltd Improved tabletting process
US20060147491A1 (en) 2005-01-05 2006-07-06 Dewitt David M Biodegradable coating compositions including multiple layers
US9205047B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US20100215744A1 (en) 2008-08-06 2010-08-26 Medicis Pharmaceutical Corporation Hydroxypropyl Substitution Used to Regulate Dissolution of a Chemical
US8920837B2 (en) 2005-07-01 2014-12-30 Rubicon Research Private Limited Sustained release dosage form
EP1898922A4 (en) 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
ZA200802602B (en) 2005-08-24 2009-10-28 Rubicon Res Pvt Ltd Controlled release formulation
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
EP1991236A2 (en) 2006-01-24 2008-11-19 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
EP2457563B1 (en) 2006-05-09 2017-03-22 Mallinckrodt LLC Zero-order modified release solid dosage forms
CA2655596C (en) 2006-06-27 2011-10-25 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
US20080014257A1 (en) 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
US20080268045A1 (en) 2006-11-09 2008-10-30 Proprius Pharmaceuticals, Inc. Sustained release methotrexate formulations and methods of use thereof
AU2007338681B2 (en) 2006-12-21 2013-09-26 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
GB0703627D0 (en) 2007-02-24 2007-04-04 Agt Sciences Ltd Aqueous formulations
WO2008104996A2 (en) 2007-02-28 2008-09-04 Jubilant Organosys Limited Water dispersible pharmaceutical formulation and process for preparing the same
JP5395052B2 (ja) 2007-03-23 2014-01-22 モレキュラー リサーチ センター インコーポレイテッド 炎症を処置するための組成物および方法
WO2009009134A1 (en) 2007-07-11 2009-01-15 Dow Corning Corporation Compositions for delivering a drug
CN101380474B (zh) 2007-09-06 2012-07-25 北京大学 用于口服制剂的pH敏感性固体药物组合物及制备方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
EP2133071A1 (en) 2008-06-09 2009-12-16 Université de la Méditerranée Process for making gastroretentive dosage forms
PL2299953T3 (pl) 2008-07-14 2017-10-31 Polypid Ltd Kompozycja nośnika leku o przedłużonym uwalnianiu
US20110268807A1 (en) 2008-08-04 2011-11-03 James Su Biodegradable Microspheres and Methods of Use Thereof
WO2010033800A2 (en) 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
EP2346351B1 (en) 2008-09-22 2019-07-03 Rubicon Research Private Limited Compositions exhibiting delayed transit through the gastrointestinal tract
DE102008048729A1 (de) 2008-09-24 2010-03-25 Add Technologies Ltd Advanced Drug Delivery Multipartikuläre Tabletten und Verfahren zur deren Herstellung
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
WO2010037545A1 (en) 2008-10-02 2010-04-08 Bayer Consumer Care Ag Compositions for treating or alleviating skin diseases or disorders related to an enhanced level of anti-microbial peptides and proteins
EP2379059A4 (en) 2008-12-10 2012-10-31 Anhui Zhongren Technology Co Ltd COMPOSITION WITH CONTROLLED RELEASE
US8524280B2 (en) 2008-12-15 2013-09-03 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
WO2010120892A2 (en) 2009-04-14 2010-10-21 The Regents Of The University Of California Improved oral drug devices and drug formulations
GB0907019D0 (en) 2009-04-24 2009-06-03 Oxford Nutrascience Ltd Pharmaceutical,therapeutic or nutritional delivery systems for functional ingredients
US20100291201A1 (en) 2009-05-14 2010-11-18 Cerovene, Inc. Coated pharmaceutical capsule dosage form
EP2435360A4 (en) 2009-05-28 2013-01-23 Univ Northwestern NANO DIAMOND PARTICLE COMPLEX
EP3144004A1 (en) 2009-10-06 2017-03-22 Scott Dorfner Antibiotic formulations providing reduced gastrointestinal side effects and clostridium difficile infection relapse, and related methods
EP2493475A4 (en) 2009-10-30 2014-10-29 Intratus Inc COSMETIC METHODS AND PREPARATIONS FOR THE PROLONGED RELEASE OF THERAPEUTIC AGENTS IN THE EYE
US9327105B2 (en) 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
US20120076766A1 (en) 2010-04-21 2012-03-29 Phillips D Howard Topical drug delivery system with dual carriers
WO2011156030A2 (en) 2010-06-11 2011-12-15 Precision Dermatology, Inc. High oil-content emollient aerosol foam compositions
US8652516B1 (en) 2013-03-15 2014-02-18 Cerovene, Inc. Doxycycline formulations, and methods of treating rosacea

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1455665A (zh) * 2000-09-19 2003-11-12 第一制药株式会社 药物组合物
US20110319368A1 (en) * 2003-04-07 2011-12-29 Supernus Pharmaceuticals, Inc. Once daily formulations of tetracyclines
US20100330131A1 (en) * 2005-06-24 2010-12-30 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
WO2007038867A1 (en) * 2005-10-04 2007-04-12 Mistral Pharma Inc. Controlled-release oral dosage form
WO2010038234A1 (en) * 2008-10-02 2010-04-08 Taro Pharmaceutical Industries Ltd. Combination product of spironolactone and doxycycline
US20120100214A1 (en) * 2010-10-21 2012-04-26 Galderma S.A. Sustained-Release Tablet and Process for Preparing the Same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
叶志雄，等: "盐酸多西环素治疗寻常痤疮130例观察", 《中国基层医药》 *
黄新闻，等: "多西环素治疗寻常痤疮的研究进展", 《临床合理用药》 *

Also Published As

Publication number Publication date
CA2906378C (en) 2021-06-22
US10842802B2 (en) 2020-11-24
CA2906378A1 (en) 2014-09-25
WO2014149674A1 (en) 2014-09-25
KR20160021074A (ko) 2016-02-24
AU2014237934A1 (en) 2015-09-24
US20140274970A1 (en) 2014-09-18
JP6417532B2 (ja) 2018-11-07
CN112007007A (zh) 2020-12-01
EP2968179B1 (en) 2019-11-06
EP2968179A1 (en) 2016-01-20
KR102298473B1 (ko) 2021-09-03
AU2014237934B2 (en) 2019-01-24
JP2016516031A (ja) 2016-06-02
EP2968179A4 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
EP2011486B1 (en) Pharmaceutical compositions of rifaximin
JP5997312B2 (ja) リファキシミンの薬剤組成物
CN101511346B (zh) 可编制的漂浮递送技术
CN101636152B (zh) 含有西洛他唑的控释制剂及其制备方法
CN101489560A (zh) 具有s形释放曲线的奥卡西平控释制剂
EP3130355A1 (en) Pharmaceutical composition containing pregabalin with improved stability and method for preparing same
WO2009047802A2 (en) Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
KR102298473B1 (ko) 제어 방출 제약 투여 형태
JP2007520547A (ja) ベンラファキシン塩酸塩の徐放性コーティングされた小型錠剤
KR20140131205A (ko) 수용성 활성성분을 함유하는 서방형 약제학적 조성물
CN101287452A (zh) 包含1-（4-氯苯胺基）-4-（4-吡啶基甲基）-2,3-二氮杂萘和pH调节剂的固体药物组合物
AU2016203925B2 (en) Pharmaceutical compositions of rifaximin
AU2014202520A1 (en) Pharmaceutical Compositions of Rifaximin
HK40041911A (en) Controlled release pharmaceutical dosage forms
WO2013018031A1 (en) Pharmaceutical compositions for gastrointestinal drug delivery
KR20060136409A (ko) 벤라팍신 히드로클로라이드의 방출연장형 코팅 미니정제

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151223